Nexomist


Nasal spray 140 sprays
scheduling status
S2
registration number
A38/21.5.1/0341
What Nexomist is and what it is used for
Nexomist is indicated to treat the symptoms of seasonal or perennial allergic rhinitis in adults, adolescents and children between the ages of 2 and 11 years. It is recommended that prophylactic treatment with Nexomist is initiated prior to the anticipated start of the pollen season in those patients who have a history of moderate to severe symptoms of seasonal allergic rhinitis.
dosage
Adults and adolescents: For both the treatment and prophylaxis of allergic rhinitis the usual recommended dose is two sprays (50 µg/spray) into each nostril once daily equal to a total dose of 200 µg per day. For maintenance therapy, once symptoms have been brought under control, a dose reduction to one spray into each nostril (total dose 100 µg per day) may be effective in some patients. If symptoms are not adequately controlled on a total dose of 200 µg per day, the dose may be increased to 4 sprays into each nostril (total dose 400 µg per day). Once symptoms are under control, it is recommended that the dose be reduced. Children between the ages of 2 and 11 years: In this population the usual recommended dose is one spray (50 µg/spray) into each nostril once daily equal to a total dose of 100 µg per day.
how to take
Before use, Nexomist nasal spray should be primed. Priming is achieved by releasing 6 or 7 actuations into the air, until a uniform spray is observed. After priming, each actuation delivers anhydrous mometasone furoate equivalent to 50 µg mometasone furoate. Repriming is required in all instances where the spray pump has not been used for 14 days or longer. If the spray pump is used regularly, no priming subsequent to initial priming is required. Shake container well before each use. Important: 1. Use Nexomist as per your doctor’s directions. The recommended dose should not be exceeded. 2. It is very important that you use Nexomist regularly, since it takes a number of days for it to work. You should not stop taking Nexomist, even if you feel better, unless your doctor has instructed you to do so. 3. Your doctor has recommended Nexomist specially for you. You should not allow any other person to use it. 4. Keep Nexomist out of reach of children. 5. Protect Nexomist from light. Use within two months of opening. How to use Nexomist: Before using: 1. Shake the bottle gently, then remove the dust cap. 2. Hold the bottle as shown with your forefinger and middle finger on either side of the nozzle and your thumb underneath the bottle. 3. Before using Nexomist for the first time or if you have not used it for longer than 14 days, follow the instructions given below: With the nozzle pointing away from you, press several times as shown until a fine uniform mist comes out of the nozzle. 4. Blow your nose gently. 5. Close one nostril and put the nozzle in the other nostril as shown. Tilt your head slightly forward keeping the nozzle in the upright position. 6. Start to breathe in through your nose and while breathing in press down with your fingers once to release a spray. 7. Breath out through your mouth. Repeat steps 6 & 7 to inhale a second spray (if indicated). 8. Repeat steps 5, 6 and 7 for the other nostril. 9. After use: Wipe the nozzle with a clean cloth and replace the dust cap. Cleansing: Nexomist should be cleaned at least once a week. To do this: 1. Push the nozzle upwards to detach from the bottle. 2. Wash the nozzle and dust cap in warm water. Shake off excess water and leave to dry in a warm place. 3. Replace the nozzle and dust cap. 4. If the nozzle becomes blocked, remove as above and soak in warm water. Rinse under a cold tap, allow to dry and refit. Do not use a pin or other sharp object to unblock the nozzle.
What Nexomist contains
50 μg mometasone furoate.
other ingredients
Anhydrous citric acid, dispersible cellulose (Avicel CL 611), benzalkonium chloride 0, 01 % (m/m) (preservative), glycerol, polysorbate 80, sodium citrate, water for injection.
Therapeutic classification
Corticosteroids.
© 2026 SAHPRA. ALL RIGHTS RESERVED